Literature DB >> 23036920

Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Melissa R Stein1, Irene J Soloway, Karen S Jefferson, Robert J Roose, Julia H Arnsten, Alain H Litwin.   

Abstract

Chronic hepatitis C virus (HCV) infection is highly prevalent among current and former drug users. However, the minority of patients enrolled in drug treatment programs have initiated HCV treatment. New models are needed to overcome barriers to care. In this retrospective study, we describe the implementation and outcomes of 42 patients treated in a concurrent group treatment (CGT) program. Patients participated in weekly provider-led group treatment sessions which included review of side effects; discussion of adherence and side effect management; administration of interferon injections; brief physical examination; and ended with brief meditation. Of the first 27 patients who initiated CGT, 42% achieved a sustained viral response. In addition, 87% (13/15) of genotype-1 infected patients treated with direct acting antiviral agent achieved an undetectable viral load at 24 weeks. The CGT model may be effective in overcoming barriers to treatment and improving adherence and outcomes among patients enrolled in drug treatment programs.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23036920      PMCID: PMC3505858          DOI: 10.1016/j.jsat.2012.08.007

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  55 in total

1.  Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.

Authors:  Shruti H Mehta; Gregory M Lucas; Lisa B Mirel; Michael Torbenson; Yvonne Higgins; Richard D Moore; David L Thomas; Mark S Sulkowski
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

2.  The relationship between substance user treatment and 12-step fellowships: current knowledge and research questions.

Authors:  Stephen Magura
Journal:  Subst Use Misuse       Date:  2007       Impact factor: 2.164

Review 3.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

4.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

5.  Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.

Authors:  D M Patrick; M W Tyndall; P G Cornelisse; K Li; C H Sherlock; M L Rekart; S A Strathdee; S L Currie; M T Schechter; M V O'Shaughnessy
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

6.  Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.

Authors:  Alain H Litwin; Irene Soloway; Marc N Gourevitch
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

7.  Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support.

Authors:  Jason Grebely; Elizabeth Knight; Krista A Genoway; Mark Viljoen; Milan Khara; Doug Elliott; Lesley Gallagher; Michelle Storms; Jesse D Raffa; Stanley DeVlaming; Fiona Duncan; Brian Conway
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-03       Impact factor: 2.566

8.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

9.  Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.

Authors:  Alain H Litwin; Kenneth A Harris; Shadi Nahvi; Philippe J Zamor; Irene J Soloway; Peter L Tenore; Daniel Kaswan; Marc N Gourevitch; Julia H Arnsten
Journal:  J Subst Abuse Treat       Date:  2008-11-28

10.  Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users.

Authors:  Markus Backmund; Kirsten Meyer; Brian R Edlin
Journal:  Clin Infect Dis       Date:  2004-10-26       Impact factor: 9.079

View more
  31 in total

1.  Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program.

Authors:  Robert J Roose; Lauren Cockerham-Colas; Irene Soloway; Abigail Batchelder; Alain H Litwin
Journal:  J Health Care Poor Underserved       Date:  2014-05

2.  Profiting and providing less care: comprehensive services at for-profit, nonprofit, and public opioid treatment programs in the United States.

Authors:  Marcus A Bachhuber; William N Southern; Chinazo O Cunningham
Journal:  Med Care       Date:  2014-05       Impact factor: 2.983

3.  Sample size determinations for group-based randomized clinical trials with different levels of data hierarchy between experimental and control arms.

Authors:  Moonseong Heo; Alain H Litwin; Oni Blackstock; Namhee Kim; Julia H Arnsten
Journal:  Stat Methods Med Res       Date:  2016-07-11       Impact factor: 3.021

4.  Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.

Authors:  Christopher Woodrell; Jeffrey Weiss; Andrea Branch; Donald Gardenier; Katherine Krauskopf; Natalie Kil; Harold Paredes; Kian Bichoupan; Keith Sigel
Journal:  J Addict Med       Date:  2015 Sep-Oct       Impact factor: 3.702

Review 5.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Authors:  Philip Bruggmann; Alain H Litwin
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

Review 6.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 7.  Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Authors:  Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

Review 8.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

9.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17

Review 10.  Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Authors:  Brianna L Norton; Matthew J Akiyama; Philippe J Zamor; Alain H Litwin
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.